全文获取类型
收费全文 | 13899篇 |
免费 | 1721篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 444篇 |
妇产科学 | 279篇 |
基础医学 | 1909篇 |
口腔科学 | 263篇 |
临床医学 | 1688篇 |
内科学 | 2810篇 |
皮肤病学 | 225篇 |
神经病学 | 1351篇 |
特种医学 | 486篇 |
外国民族医学 | 1篇 |
外科学 | 1855篇 |
综合类 | 316篇 |
一般理论 | 9篇 |
预防医学 | 1514篇 |
眼科学 | 228篇 |
药学 | 1319篇 |
中国医学 | 21篇 |
肿瘤学 | 738篇 |
出版年
2021年 | 229篇 |
2020年 | 142篇 |
2019年 | 225篇 |
2018年 | 293篇 |
2017年 | 176篇 |
2016年 | 212篇 |
2015年 | 217篇 |
2014年 | 309篇 |
2013年 | 396篇 |
2012年 | 621篇 |
2011年 | 635篇 |
2010年 | 354篇 |
2009年 | 358篇 |
2008年 | 614篇 |
2007年 | 616篇 |
2006年 | 587篇 |
2005年 | 569篇 |
2004年 | 536篇 |
2003年 | 505篇 |
2002年 | 516篇 |
2001年 | 495篇 |
2000年 | 436篇 |
1999年 | 403篇 |
1998年 | 189篇 |
1997年 | 195篇 |
1996年 | 184篇 |
1995年 | 179篇 |
1994年 | 164篇 |
1993年 | 151篇 |
1992年 | 402篇 |
1991年 | 334篇 |
1990年 | 304篇 |
1989年 | 298篇 |
1988年 | 329篇 |
1987年 | 291篇 |
1986年 | 264篇 |
1985年 | 214篇 |
1984年 | 245篇 |
1983年 | 189篇 |
1982年 | 138篇 |
1981年 | 115篇 |
1980年 | 113篇 |
1979年 | 190篇 |
1978年 | 121篇 |
1976年 | 135篇 |
1975年 | 125篇 |
1974年 | 119篇 |
1973年 | 109篇 |
1972年 | 113篇 |
1970年 | 108篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
1. The action of (1-28) alpha-human atrial natriuretic peptide (ANP) was studied on human isolated resistance arteries. 2. Renal, skeletal muscle, omental and subcutaneous resistance arteries were taken from tissue removed at surgery and isometric tension responses were measured with a myograph. 3. ANP (10(-9)-10(-6) M) relaxed precontracted segments of renal and skeletal muscle arteries in a concentration-dependent manner. ANP failed to relax isolated omental or subcutaneous arteries. 4. The effect of ANP on human isolated resistance arteries varies depending on the site of origin of the artery. 相似文献
12.
Betsy D. Kennard Susan G. Silva Simon Tonev Paul Rohde Jennifer L. Hughes Benedetto Vitiello Christopher J. Kratochvil John F. Curry Graham J. Emslie Mark Reinecke John March 《Journal of the American Academy of Child and Adolescent Psychiatry》2009,48(2):186-195
ObjectiveWe examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS).MethodThe TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive–behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.ResultsAt week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive–behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36.ConclusionsMost depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment. 相似文献
13.
14.
The activation of phospholipase A2 is believed to have an important role in the inflammatory process owing to its induction of eicosanoids, platelet activating factor, and other mediators. Soluble phospholipase A2 has been associated with exudates in different inflammatory conditions. In this review the general physiology and control of this enzyme and, in particular, the most recent findings on human synovial fluid phospholipase A2s are discussed. 相似文献
15.
16.
J Chhabra Y-Z Li H Alkhouri A E Blake Q Ge C L Armour J M Hughes 《The European respiratory journal》2007,29(5):861-870
Degranulating mast cells are increased in the airway smooth muscle (ASM) of asthmatics, where they may influence ASM function. The aim of the present study was to determine whether histamine and tryptase modulate ASM cell granulocyte-macrophage colony-stimulating factor (GM-CSF) and RANTES (regulated on activation, normal T-cell expressed and secreted) release and also to examine which receptors are involved in this release. Confluent, quiescent ASM cells from asthmatic and nonasthmatic donors were treated with histamine (1 microM-100 microM) with and without histamine receptor antagonist pre-treatment, or the protease-activated receptor (PAR)-2 agonists tryptase (0.5-5 nM) and SLIGKV (100 and 400 microM). The cells were then stimulated with interleukin (IL)-1beta and/or tumour necrosis factor (TNF)-alpha (10 ng.mL(-1)) or left unstimulated for 24 h. Release of GM-CSF and RANTES was determined by ELISA and prostaglandin (PG)E(2) measured by enzyme immunoassay. Neither histamine nor tryptase induced ASM GM-CSF or RANTES secretion. However, histamine increased IL-1beta-induced GM-CSF release and markedly reduced TNF-alpha-induced RANTES release by both asthmatic and nonasthmatic cells to a similar extent, but did not modulate PGE(2) release. All changes involved activation of the histamine H1 receptor as they were partially or fully blocked by chlorpheniramine, but not ranitidine. Tryptase, via its proteolytic activity, also potentiated GM-CSF, but not RANTES, release from asthmatic and nonasthmatic ASM cells induced by both cytokines. PAR-2 involvement in the tryptase potentiation was unlikely because SLIGKV had no effect. In conclusion, mast cells, through histamine and tryptase, may locally modulate airway smooth muscle-induced inflammation in asthma. 相似文献
17.
The effect of concomitant disorders in childhood depression on predicting treatment response 总被引:2,自引:0,他引:2
C W Hughes S H Preskorn E Weller R Weller R Hassanein S Tucker 《Psychopharmacology bulletin》1990,26(2):235-238
Children with pure depression or depression plus an anxiety-related disorder (n = 14) had a higher drug response rate (57%) and a lower placebo response rate (20%) when compared to children with depression plus a concomitant conduct or oppositional disorder (n = 17) (33% drug response rate and 67% placebo response rate). These findings could explain why studies of prepubertal-onset depression found no differences between drug and placebo treatment assuming that a large percentage of the studies' subjects had concomitant conduct or oppositional disorders. The children with pure depression or depression plus an anxiety-related disorder had different symptom clusters from those with depression plus a concomitant conduct or oppositional disorder. The former had more severe CDRS ratings on sleep, appetite disturbance, depressed feelings, and psychomotor retardation. In contrast, those with a concomitant conduct or oppositional disorder had shorter attention spans and were more likely to disturb other children (based on Conners scale scores). 相似文献
18.
A. Robert Spitzer Shalom Stahl David Yarnitsky Ernest W. Johnson John R. Wilson R. A. C. Hughes Stefania Morino Giovanni Antonini Kiyotoshi Kaneko Yoji Ohnishi Tetsushi Atsumi Isao Hozumi Tadashi Miyatake Tetsuo Furukawa James P. Knochel Ikuo Mineo Seiichiro Tarui Francis O. Walker Andrew J. Gitter Walter C. Stolov Nicholas J. Capozzoli 《Muscle & nerve》1996,19(4):531-538
19.
Young physicians and the future of the medical profession 总被引:1,自引:0,他引:1
20.
Dr. Barbara McGee Hughes Pharm.D. Dr. Ralph E. Small Pharm.D. Dr. Douglas Brink Pharm.D. Dr. Norma D. McKenzie M.D. 《Pharmacotherapy》1997,17(1):113-120
Study Objective . To evaluate the effects of flurbiprofen therapy on the pharmacokinetics of lithium. Design . Placebo-controlled, single-blind, crossover study. Setting . University-affiliated hospital. Patients . Eleven healthy women with bipolar disorder. Interventions . The subjects received therapeutic doses of lithium administered as an immediate-release capsule every 12 hours. In addition, they received one placebo tablet every 12 hours during phase I and flurbiprofen 100 mg every 12 hours during phase II of the study. Measurements and Main Results . Steady-state pharmacokinetic parameters were measured for each phase. Lithium trough plasma concentration (Cmin) and area under the curve were statistically significantly increased (p<0.05) when patients received flurbiprofen. Flurbiprofen also caused decreases in lithium clearance and 24-hour lithium urine excretion, although the changes did not reach statistical significance. Clinically significant increases in Cmin appeared to be associated with a greater than 1000-μg/24 hour decrease in urinary excretion of prostaglandin E2. Conclusion . Patients with clinically normal renal function may experience an increase in lithium levels with the initiation of flurbiprofen therapy. 相似文献